EurActiv Logo
 
9 November 2009
Breaking News:
News

G10 Medicines Group makes recommendations to enhance pharmaceutical competitiveness 

Published: Friday 1 March 2002   

On 26 February 2002, the G10 Medicines Group adopted recommendations to enhance competitiveness in the pharmaceutical industry while sustaining high public health standards.

Background:


The G10 Medicines Group was set up by Commissioners Liikanen and Byrne in the March 2001. The "High Level Group on Innovation and Provision of Medicines" consists of two EU Commissioners (Enterprise Commissioner Erkki Liikanen and Health Commissioner David Byrne), a number of European health and industry ministers, as well as leaders of the pharmaceutical and health insurance industry and patient representatives.

 

Other related news:


The G10's recommendations for action at European and national level covers several key areas including:

  • improving the working of the pharmaceuticals market:
    • develop a set of performance and competitiveness indicators (benchmarking);
    • shorten the time between granting a marketing authorisation and pricing and reimbursement decisions;
    • develop a competitive generic market, tackling intellectual property right issues;
    • develop a competitive market for non-prescription medicines;
    • find ways of sharing information and data;
    • develop a health technology assessment (HTA), including clinical and cost effectiveness;
    • improve the use of telematics.
  • stimulating innovation and strengthening the European science base:
    • improve the legislation and licensing system for introducing innovative medicines on the market;
    • create European virtual institutes of health, connecting all competence centres ("network of excellence");
    • improve coordination at EU level for clinical trials, a biotechnology strategy, an incentive policy to support research and the marketing of paediatric and orphan medicines;
    • no advertising restrictions on non-prescription medicines.
  • producing better information for patients:
    • legislation on patient information leaflets should be reviewed;
    • post-marketing surveillance should be optimised;
    • fund European patient groups.
The Group is also fostering transparency and the active involvement of a wide range of interested parties through a number of concrete actions, such as the launch of a G10 Medicines Website, the publication of a consultation paper and a programme of workshops.

 

Next steps:


The G10's recommendations will be set out in a report, which will be presented to the European Commission President Romano Prodi in early May 2002, on "G10 Medicines Info Day".

 

Links

Letters To The Editor
A propos de la crise de la nouvelle grippe A(H1N1)
Pedro Obando, Belgique
Concerns over mercury use in dental amalgam
Genon Jensen, Executive Director, Health and Environment Alliance
Send a Letter To The Editor
Advertising
Agenda
  1. 26 November 2009
    ECPA Food Supply Forum
Communicate your event
 
Section Sponsors
Microsoft
 
Advertising